Xconomy Wisconsin — After less than a year, Exact Sciences has terminated a partnership with the University of Texas MD Anderson Cancer Center aimed at developing blood-based diagnostic tests for lung cancer.
The decision to nix the agreement was mutual, MD Anderson’s Sam Hanash said in an e-mail to Xconomy. Hanash is a physician and researcher at the cancer center, which is in Houston.
The main reason for ending the collaboration, which was announced in June, was its potentially high cost, Exact CEO and chairman Kevin Conroy said during an earnings call with financial analysts on Wednesday.
